Back to today’s briefing

Story perspectives

EpiReg-T Silences PCSK9: A Breakthrough in Gene Targeting

10/2/2025

43 10 Full Breakdown

Summary

Story summary

EpiReg-T achieves over 90% silencing of PCSK9 in nonhuman primates, per Nature Biotechnology.
The method uses lipid nanoparticles for safe, non-viral administration, maintaining repression up to 343 days.
The design enables customizable gene targeting with potential in cancer, inflammatory diseases, and rare disorders.
Epigenetic editing is a reversible alternative to genome editing; future work will assess clinical scalability and safety.

1 of 1

Story summary

EpiReg-T achieves over 90% silencing of PCSK9 in nonhuman primates, per Nature Biotechnology.
The method uses lipid nanoparticles for safe, non-viral administration, maintaining repression up to 343 days.
The design enables customizable gene targeting with potential in cancer, inflammatory diseases, and rare disorders.
Epigenetic editing is a reversible alternative to genome editing; future work will assess clinical scalability and safety.